Enhancing Respiratory Disease Research with Wearable DHTs
Establishing clinical benefit is one of the most challenging and costly steps in developing a new therapy for patients with respiratory diseases such as asthma, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. Symptoms of respiratory diseases can affect patients in many ways, including their physical functioning, mobility, and sleep.
With the advent of sensor-based digital health technologies (DHTs), we now have an unprecedented opportunity to remotely and continuously assess how study participants in respiratory disease research function in their daily lives.
This digital endpoints guide provides information on wearable DHT adherence in respiratory disease clinical trials, a list of digital endpoints available for respiratory disease trials, and opportunities to advance respiratory disease research with wearable DHTs, including:
- Supporting patient-centric respiratory disease drug development with easy-to-use wearable technology
- Collecting previously inaccessible clinical insights for respiratory disease trials through novel digital endpoints
- Passively examining physical activity, gait and mobility, sleep behavior, and vital signs in the patient’s natural environment
Advancing Respiratory Disease Research with Digital Measures
Clinical development in respiratory diseases has seen the most progress in regulatory acceptance of digital endpoints. Read more about a digital measure of physical activity approved by the FDA as a primary endpoint in a Phase 3 pulmonary fibrosis trial:
